To strengthen the biotechnology sector, the Saudi Ministry of Industry and Mineral Resources, in partnership with the Kingdom's Ministries of Investment and Health, has signed a Memorandum of Understanding (MoU) with Vertex, an American pharmaceutical company. The agreement aims to transfer knowledge, develop innovations and research locally, and localize gene therapy manufacturing in the Kingdom.
By 2040, the alliance hopes to assist Saudi Arabia in realizing its vision of being a global center for biotechnology. Over the following five years, it is anticipated to bring up to SAR 1 billion in investments to the Kingdom.
Through three main pillars—developing research, development, and medical treatment expertise within the Kingdom; bolstering local biomanufacturing capabilities in cell and gene therapy; and training and qualifying local talent to accelerate the development of Saudi health experts—the MoU seeks to place the Kingdom at the forefront of the global biotechnology landscape.
CMI Research: Key Cell and Gene Therapy Market Insights
According to Coherent Market Insights (CMI), the cell and gene therapy market is expected to exhibit a CAGR of 28.7% between 2023 and 2030, driven by the growing use of a variety of growth methods, including product launch and approval. By 2030, the market is expected to have grown significantly from its 2023 valuation of US$ 22.7 billion.
The market is anticipated to increase over the projected period because to the increasing adoption of various research and development efforts by market participants for a variety of illness conditions, including Huntington's disease and moderately severe hemophilia B.
Analyst Opinion: Strategic Role in Cell and Gene Therapy Growth
Senior management consultant Abhijeet Kale claims that the rise of the therapy type sector in North America is being driven by the major market participants' increasing investments to expand their skills in advancing gene therapy. For example, the pharmaceutical corporation Pfizer Inc. declared in December 2021 that it had been investing US$ 800 billion to construct manufacturing facilities that would support the production of gene therapy from preclinical research to commercial scale production.
Conclusion: Business Takeaways
Overall, cell and gene therapy has enormous commercial potential, there are several obstacles to overcome, such as difficult legal requirements, expensive production, and moral dilemmas. Companies should prioritize effective production techniques, strategic alliances, and customized international expansion plans. Long-term viability will depend on patient-centered pricing and personalized medicine models. In order to succeed in this quickly expanding industry, one must navigate business, regulatory, and scientific dynamics while upholding moral principles and openness.
